Cost-effectiveness of osimertinib versus placebo in resected EGFR-mutated non-small cell lung cancer in China.

Xiwen ZhouJianting DuGuobing XuChun ChenBin ZhengJiahe Chen

Published in: Cancer medicine (2022)

From the perspective of the Chinese Healthcare System, the treatment strategy with osimertinib postoperative adjuvant therapy is more cost-effective than the placebo strategy.

Keyphrases

small cell lung cancer
epidermal growth factor receptor
advanced non small cell lung cancer
tyrosine kinase
double blind
patients undergoing
lymph node
phase iii
placebo controlled
study protocol